Agilent Technologies (A)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$131.13+0.41%
Close 2026-07-07 · 1-day change
Reading A? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track A free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading A? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track A free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on revenue growth and earnings per share (EPS) targets. The current thesis state is intact, bolstered by recent financial results, but management execution remains a concern.
The market appears to have priced in a neutral valuation, reflecting a slight divergence as A is seen as cheap compared to its peers. There is a low level of fragility in execution quality, suggesting that the market does not fully account for potential weaknesses.
Fundamentals are likely to remain stable, with management on track to meet revenue and EPS targets for fiscal year 2026. However, there is a moderate risk of missing expectations, given the company's recent history of misses.
The thesis hinges on management's ability to maintain guidance and deliver on operational transformation. Additionally, the performance of sector bellwethers like TMO, DHR, and IDXX will be crucial in determining A's momentum.
Overall, A's performance is solid, but it faces challenges that could impact its trajectory. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat and positive revenue growth for fiscal year 2026 support this improved outlook. There are no new threats identified that would weaken the thesis.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show if Agilent meets its revenue and EPS guidance. This impacts investor confidence.
Confirms one read:Q3 2025 revenue and EPS meet or exceed the guidance range of $7.39-$7.49 billion and $6.00-$6.10 respectively.
Confirms the other:Q3 2025 revenue and EPS fall below the guidance range.
Why it matters: Revenue growth is a key priority. Strong growth signals effective execution of Agilent's strategy.
Confirms:Revenue growth for fiscal year 2026 exceeds the guidance of $7.39-$7.49 billion.
Disproves:Revenue growth falls short of the guidance range.
Why it matters: The CFO change is important for money stability and plans. A smooth change can build trust.
Confirms:Announcement of a new CFO who has relevant experience and a strong track record.
Disproves:Prolonged delay in naming a new CFO or issues arise during the transition.
Why it matters: Progress on this initiative is crucial for Agilent's growth. Delays could signal deeper issues.
Confirms:Management says they are improving operations. They see clear results from these changes.
Disproves:Management says the changes in operations are late and lacks clear plans to fix it.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.